Short answer
Kenvue (KVUE) filed its Q3 2025 10-Q quarterly report on Nov 3, 2025 for the quarter ended Sep 28, 2025. Quarterly revenue was $3.8B (down 3.5% year over year) with net income of $398M.
Q3 2025 key financials · XBRL
- Revenue
- $3.8B
- −3.5% YoY · −2.0% QoQ
- Net income
- $398M
- +3.9% YoY · −5.2% QoQ
- Operating margin
- 16.7%
- Gross margin
- 59.1%
- EPS (diluted)
- $0.20
- +0.0% YoY · −9.1% QoQ
Source: XBRL data from the Kenvue (KVUE) Q3 2025 10-Q on SEC EDGAR. USD.
Kenvue Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $3.76B, down 3.5% YoY ($135M decrease from $3.9B)
- Gross profit margin up 59.1% vs 58.5% YoY; operating income down 3.8%
- Skin Health & Beauty worst performer: sales down 3.2%, adjusted operating income down 28.3%
- Essential Health best performer: adjusted operating income up 5.5% despite 3.3% sales decline
- Operating cash flow up 37.6% YoY to $1.34B; increased investing outflow to $361M; dividend paid $1.18B in 9 months
- Management approved merger with Kimberly-Clark to complete in 2H 2026; faces acetaminophen regulatory risks impacting Tylenol sales
Risk Factors
- Newly added risk: Transaction financing increasing K-C’s debt, potentially reducing liquidity and flexibility before closing
- Most materially updated risk: $1,136M termination fee added if Transaction terminated under certain conditions, increasing financial exposure
- Regulatory risk: Transaction requires multiple approvals; regulatory conditions or delays may impose costs or restrict combined company’s operations
- Operational risk: Management distraction and key employee loss risks amid Transaction pendency threatening business continuity and integration
- Financial risk: Post-Transaction indebtedness could impair debt service, causing liquidity stress and forcing asset sales or capital raises
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Kenvue quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.